anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An enteral nutrition comprises (mass%) marine bioactive polysaccharide 0.5-0.8%, enzymolysis article of shell fish meat 25-35%, fruit and vegetable powder 10-20%, and sodium-iron-EDTA 0.05-0.1%. The marine bioactive polysaccharide can be Pinctada martensii glycosaminoglycan, sea cucumber chondroitin sulfate or fishbone chondroitin sulfate. The enteral nutrition can further comprise soy protein isolate 35-45%, kelp powder 1-5% and refined konjak powder 3-5%. The enteral nutrition has high heat, high protein, high iron, low fat, multiple vitamins and easy absorbability. It is used as food for people needing much iron, especially for leukemia patient, bone marrow transplantation patient. It is also used with chemotherapy medicine to increase the curative effect of the medicine, improve the functions of gastrointestinal tract, enhance the immunity, and reduce side effects such as anemia and accompanying infection. Its preparation method includes that the raw materials are crushed with 60 meshes sieve and sterilized for 2 minutes with 800 kW power microwave after mixing and drying.
Panic Disorder (PD) is one of the most common anxiety disorders. In spite of several available medications, there are unsatisfactory outcomes in a considerable proportion of PD patients and novel treatment approaches are lacking. Given that response to pharmacotherapeutical and psychological treatments occur after long intervals and medications may cause substantial adverse effects which may affect treatment compliance, fast acting and well-tolerated treatments such as non-invasive brain stimulation are considered to be useful as primary treatment approach or as an add-on treatment in PD. Repetitive Transcranial Magnetic Stimulation (rTMS) trials targeting prefrontal cortex mostly reported favorable outcomes in PD.

Transcranial Direct Current Stimulation (tDCS) is another promising non-invasive brain stimulation method with numerous distinctive aspects including its low-cost, robust safety and tolerability, low dropout rates, easy application, reliable blinding procedures and the opportunity to use concomitantly with other treatments. Left anodal/right anodal tDCS over the dorsolateral prefrontal cortex has been demonstrated to decrease attentional bias and amygdala reactivity to threat in individuals with high trait anxiety. Moreover, a treatment-resistant case of PD was reported to have significant amelioration of symptoms up to one month after 10 sessions of tDCS.

The study is a triple-blind randomized controlled trial. The sample will be consisted of thirty participants diagnosed as having PD due to Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria. The participants will be assigned to active or sham groups equally. Clinical severity will be assessed with adequate scales. Emotion recognition, attentional bias to threat and interoceptive accuracy will also be measured. Then, participants will be applied ten active or sham sessions of left anodal/right cathodal tDCS over the dorsolateral prefrontal cortex (DLPFC). All measurements will be repeated after the applications. Succinctly, the aim of this study is to assess the effect of ten sessions left anodal/right cathodal tDCS over the DLPFC on clinical severity, attentional bias and interoceptive accuracy in PD.
Fluvestrant in combination with oral Vinorelbine Fluvestrant: administered at a dose of 0.5g once im every 28 days. Vinorelbine: administered at a dose of 60mg/kg once a week for 3 weeks p.o. every 28 days.
Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa L., has been purported to have a variety of beneficial physiological effects including but not limited to, pain relief, anti-anxiety, anti-seizure, anti-depressant, anti-oxidant, and anti-inflammatory. Despite the enthusiasm of the CBD industry for these claims, the empirical evidence supporting favourable physiological responses is inconsistent. These discrepancies may in part be explained by differences in CBD bioavailability when administered orally that in turn may be influenced by non-standardized CBD formulation, and/or the body size and composition of the recipient.

The purpose of this study was to test the bioavailability of two doses of a novel CBD formation given twice per day for three consecutive days in healthy study subjects and explore their potential acute anti-inflammatory properties as assessed by highly sensitive immunologic assays. The rationale for conducting the study was to evaluate the pharmacokinetic (PK) profile of a novel formulation of CBD designed to improve bioavailability given at two dose levels twice per day for three consecutive days. Although previous studies conducted in healthy study subjects have documented the safety and PK profile for a single dose of the test product, multiple ascending dose studies have not yet been conducted. In addition to evaluating multiple ascending dose PK, the pharmacodynamic properties of the CBD were assessed using ex vivo lipopolysaccharides (LPS) stimulated whole blood assays and high sensitivity serum cytokine assays.
It was planned as a non-invasive reliability study. The validity and reliability of 6PBRT in obese individuals will be investigated within the scope of the study. In this context, a 1-hour rest break will be given after the first test. Dyspnea and fatigue will be evaluated using the Borg scale and muscle oxygenation, heart rate and blood pressure will be recorded before and after 6PBRT. The second trial of 6PBRT will be performed after the 1-hour rest period. In order to ensure that the patients are stable, the level of dyspnea and fatigue and the initial values of heart rate will be checked before the second trial. All evaluations will be made by the same physiotherapist and an expert physiotherapist will be present during the evaluations.

The smallest sample size of the study was found to be 40 people with a correlation coefficient of 0.95 between the two tests and 90% power at a 95% confidence interval. It is aimed to include 50 people against a 20% drop-out risk.

Shapiro-Wilk test and histogram graphics will be used to check the normality of the data. Demographic and clinical characteristics of the participants will be reported using descriptive statistics. Intraclass correlation coefficient (ICC) with two-way random effects and absolute agreement methods will be used to assess test-retest reliability. The strength of reliability will be interpreted as excellent for ICC value \&amp;amp;gt;0.90. Ninety-five percent Confidence Interval (95% CI) will be calculated to investigate measurement variability.
PURPOSE:A remedy for psoriasis containing an active type vitamin D3 as an active constituent. CONSTITUTION:A remedy for dermatopathy obtained by incorporating an active type vitamin D3, e.g. 1alpha,24(R)-dihydroxycholecalciferol, as an active constituent and effective for psoriasis, e.g. psoriasis vulgaris, psoriasis pustulosa, psoriasis guttata, psoriasis erythrodermia, psoriasis arthropathica, psoriasis gravis, etc. The remedy is administered by either one of oral and parenteral routes, but normally percutaneously administered preferably in the form of an external drug. In the case of the psoriasis arthropathica and psoriasis gravis, the remedy is preferably administered preferably in the form of an oral agent. Examples of the external drug include an ointment, cream, lotion or tape agent consisting essentially of an oleophilic base, etc. The dose thereof is 200-0.1mug/g external drug twice a day for percutaneous administration and 0.05-50mug/day for oral administration.
The presence of a significant mitral regurgitation (MR) seriously effects the patient's quality of life and is associated with an increased mortality rate. The operative treatment of MR - either mitral valve repair or replacement - is the current gold standard. However mere half of the patients with a severe and symptomatic MR actually undergo an operative treatment (EURO-HEART-SURVEY) due to restricted left ventricular ejection fraction, elderly patients with co-morbidities and high perioperative morbidity and mortality. In contrast, patients with severe and symptomatic MR not suitable for operation are treated with palliative medical therapy (heart insufficiency therapy). With the development of the MitraClip device - a minimal-invasive, percutaneous catheter-based technique - high-risk patients not suitable for surgery may receive a promising alternative treatment by approximating the mitral leaflets, thus creating a permanent leaflet coaptation and reducing or even abrogating the MR. The current data support the assumption of a safe and effective MR reduction with the MitraClip-System in inoperable high-risk patients with severe MR. But the feasibility still has to be proven in this special patient population.
After completing the pre-test survey, participants from all intervention groups will receive the written information. Subsequently, they will be randomly assigned to one of the intervention groups. The K-Bot group will only interact with the chatbot via the web-based platform or KakaoTalk for 3 months.
Disease-modifying therapies for Alzheimer's disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes. Here, we update and complement previous findings from the Dominantly Inherited Alzheimer Network Observational Study by using matched cross-sectional and longitudinal cerebrospinal fluid (CSF) and plasma samples from 567 individuals, allowing timely comparative analyses of CSF and blood trajectories across the entire disease spectrum. CSF and plasma trajectories were similar at presymptomatic stages, discriminating mutation carriers from non-carrier controls 10-20 years before the estimated onset of clinical symptoms, depending on the statistical model used. However, after symptom onset the rate of change in CSF NfL continued to increase steadily, whereas the rate of change in plasma NfL leveled off. Both plasma and CSF NfL changes were associated with grey-matter atrophy, but not with Aβ-PET changes, supporting a temporal decoupling of Aβ deposition and neurodegeneration. These observations support NfL in both CSF and blood as an early marker of neurodegeneration but suggest that NfL measured in the CSF may be better suited for monitoring clinical trial outcomes in symptomatic AD patients.
Patients receive ferumoxytol non-stoichiometric magnetite IV on day 2 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose). Ferumoxytol non-stoichiometric magnetite administration continues in the absence of unacceptable toxicity.
Patients are instructed in extension exercises and actually, physically doing the actual extension exercises. Patients will physically repeat the extension exercises 10 times while in the clinic, after which they will be instructed in a home program containing the same treatment - every 2 hours, perform 10 exercises.
Oxaprozin tablets, USP is a nonsteroidal anti-inflammatory drug (NSAID), chemically designated as 4,5-diphenyl-2-oxazole-propionic acid, and has the following chemical structure:

The molecular formula for oxaprozin is C 18H 15NO 3, and the molecular weight is 293. Oxaprozin is a white to off-white powder with a slight odor and a melting point of 162°C to 163°C. It is slightly soluble in alcohol and insoluble in water, with an octanol/water partition coefficient of 4.8 at physiologic pH (7.4). The pK a in water is 4.3. 

Each tablet, for oral administration, contains 600 mg of oxaprozin. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, , magnesium stearate, methylcellulose, polyethylene glycol, stearic acid and titanium dioxide.
Baihuawang liquid is compound Chinese medicinal preparation prepared by extracting from main raw materials including honey, honeycomb, raw rehmannia glutinosa, fruit of Chinese magnoliavine, medlar, ginseng and other medicinal materials; and from appearance and traits, Bahuawang liquid is brown liquid. The formula of the Bahuawang liquid mainly comprises: 400 grams of honey, 450 grams of honeycomb, 30 grams of raw rehmannia glutinosa, 50 grams of fruit of Chinese magnoliavine, 30 grams of medlar and 40 grams of ginseng. The Bahuawang liquid is used for treating leukaemia by being taken alone in a volume of 20 to 25 milliliters three times each day and by being taken for two treatment periods each of which is 15 days long. The Bahuawang liquid has the advantages of avoiding chemotherapy, blood transfusion and bone marrow transplantation, killing leukemia cancer cells, avoiding hurting normal cells, avoiding side effects, along with quick effectiveness, short treatment period and high cure rate. The Bahuawang liquid project has been listed in the scientific plan for social development field in Guangzhou (see figure 5 Document from Department of Science and Technology of Guangdong Province). Notes for figure in the abstract in the description: 01, appearance and traits of 10-year Baihuawang liquid; 02, appearance and traits of 8-year Baihuawang liquid; 03, appearance and traits of 4-year Baihuawang liquid; and 04, appearance and traits of 2-year Baihuawang liquid.
The cardioprotective effects of nuts have been well documented in the scientific literature; however, most of the research has been done with almonds, walnuts, and pistachios, while studies with cashew nuts are lacking. In addition to the cardiovascular literature, our recent studies measuring the metabolizable energy of nuts have demonstrated that the measured energy value of almonds, pistachios, and walnuts is lower than that predicted using the Atwater factors. However, the measured energy value of cashew nuts is unknown. There are two distinct aims of this study - determining the effects of cashew nut consumption on risk factors of CVD, and determining the energy value of cashew nuts in the human diet. The cardiovascular effects of cashew nuts will be determined by measuring both traditional and emerging risk factors. The metabolizable energy value of cashew nuts will be calculated based on the chemical composition and energy content of the consumed diet and excreta. This will provide a better estimate of the energy value than simply calculating energy value based on Atwater factors.
This study is designed to assess the tolerability of different forms (liquid, capsules or tablets) of lopinavir/ritonavir given once-daily as part of combination therapy for HIV infection. Study subjects will be those tolerating a stable regimen of HIV medications with undetectable levels of HIV in their blood. They will be assigned by chance to receive once daily liquid or soft gel capsules of lopinavir/ritonavir for up to four weeks. At that time they will receive the alternative formulation for up to four weeks. They will then be given once daily lopinavir/ritonavir in the recently released tablet formulation. After up to four weeks of each of these formulations several assessments will be made of the overall tolerability of the drug. After four weeks of tablets they will be allowed to take whatever regimen they want and will be followed for an additional 36 weeks for a total duration of study of up to 48 weeks. The pharmacokinetics of each formulation of lopinavir/ritonavir given once daily will also be assessed in a subset of study subjects.
PURPOSE:To utilizie the soluble eggshell film as a covering material for skin disease by constituting the film to a sheet form. CONSTITUTION:Thoouh an eggshell film itself is insoluble in water or organic solvents in ordinary case, a water-soluble eggshell film can be obtained by treating the eggshell by an acid, alkali, organic solvent, oxidizing agent, a reducing agent, etc. As the reducing agent, mention is made of beta- mercaptoethanol, thioglycol adid, etc. The soluble eggshell film can be formed to a sheet form on plane view, and as the representative example, mention is made of a sheet which is formed by using mainly the soluble eggshell film, the sheet which is manufactured by using the material (e.g. plastic) other than eggshell film and whose surface is covered or coated with the soluble eggshell film, i.e., the sheet which is shaped to a sheet integrally with other sheet. Accordingly, the sheet can be used in a suitable manner as the covering material for the skin disease.
PROBLEM TO BE SOLVED: To obtain the subject composition having high ameliorating effect on dirty blood, namely high effect having dense blood and high viscosity and improving conditions having bad fluidity by including Enkianthus perulatus as a main ingredient. SOLUTION: This composition contains Enkianthus perulatus as a main ingredient. The grass is preferably used by extracting whole grass of Enkianthus perulatus with water or a lower alcohol under heating and powdering the extract so as to make administrable form. Combined use of Enkianthus perulatus and leaf of Salvia miltiorrhiza which is a labiate is preferable because of large ameliorating effect on dirty blood. Further, Mucunae caulis, root of Dalbergia odorifera T. Chen, Crateagi fructus, Curcumae rhizoma, Cinnamonome cortex, Zingiberis rhizoma, Citri leiocarpae exocarpium and Ginseng radix can be formulated. Enkianthus perulatus is preferably formulated in an amount of >=40wt.% and Salvia miltiorrhiza is preferably formulated in an amount of <=15wt.%. Other components such as root of Dalbergia odorifera T. Chen and Crateagi fructus are each formulated in an amount of <=10wt.%.  Furthermore, the composition has effects on increase of cerebral blood flow, blood lipid, etc., and can safely be administered.
Multi-center prospective data recording study. All patients will receive standard medical care and no experimental interventions will be performed.

All patients scheduled to undergo ESD at the University of Florida and participating centers as medically indicated will be considered for the study. Patients in whom ESD is considered as part of their standard medical care will be offered to participate in this study. The physician performing the procedure will also discuss the study with the subjects. If the patient agrees to participate, he or she will be given the informed consent form and allowed enough time to read it. Opportunity to ask questions will be provided. If the patient agrees to participate, he or she will sign the consent form and a copy will be provided. Data will be prospectively recorded according to the data collection form. ESD will be performed as medically indicated. The investigators from each respective center on this project will also be in charge of the medical care of the patients enrolled in the study. Follow-up will be carried out as medically indicated and no additional studies or clinic visits will be needed specifically for the purpose of this study.
This invention designs and builds multiple layers (two layers or more) of millable dental blocks or disks for milling of various dental devices, specifically denture base blocks or disks of denture base material, where milled teeth cavities to receive artificial denture tooth materials to form final dental devices, such as partial and full dentures. This invention also designs and builds multiple layers (two layers or more) of millable denture base or denture blocks or disks comprised of denture base or/and denture tooth materials to form final dental devices, such as partial and full dentures. A method for manufacturing a layered denture is provided. The invention provides a multiple layered denture base block (or disk) for milling a denture base. The invention also provides a multiple layered denture block (or disk) for milling a denture. Highly shape adjustable or shape memory polymer layer(s) may be used in these multiple layered forms. Different layer of material has different mechanical and physical properties to meet different need, which provide added benefits to the patients, dental professional and dental laboratory.
This study is conducted according to the tenets of the Declaration of Helsinki. All participants are recruited at the Shanghai Mental Health Center (SMHC) or its affiliate, the Shanghai Psychotherapy and Psychological Counseling Center (SPCC) with written informed consent, approved by the Research Ethics Committee of SMHC. For those younger than 18 years, both the adolescents and their next of kin or legal guardians are provided informed consents. The outpatients are recommended by doctors to participate in our CHR screening. After being screened and interviewed, those who meet the inclusion criteria are informed and signed written informed consent. Once the subjects are recruited, clinical evaluation, VHI and MCCB test will be conducted. In addition, CHR individuals will be followed up at one-year node.
Patients received Carbidopa/levodopa/entacapone tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
BACKGROUND: Areca nut polyphenols (AP) that extracted from areca nut, have been demonstrated for their potential of anti-fatigue effects. However, the underlying mechanisms for the anti-fatigue properties of AP has not been fully elucidated to date. Previous studies have predominantly concentrated on single aspects, such as antioxidation and anti-inflammation, yet have lacked comprehensive multi-dimensional analyses.
PURPOSE: To explore the underlying mechanism of AP in exerting anti-fatigue effects.
METHODS: In this study, we developed a chronic sleep deprivation-induced fatigue model and used physiological, hematological, and biochemical indicators to evaluate the anti- fatigue efficacy of AP. Additionally, a multi-omics approach was employed to reveal the anti-fatigue mechanisms of AP from the perspective of microbiome, metabolome, and proteome.
RESULTS: The detection of physiology, hematology and biochemistry index indicated that AP markedly alleviate mice fatigue state induced by sleep deprivation. The 16S rRNA sequencing showed the AP promoted the abundance of probiotics (Odoribacter, Dubosiella, Marvinbryantia, and Eubacterium) and suppressed harmful bacteria (Ruminococcus). On the other hand, AP was found to regulate the expression of colonic proteins, such as increases of adenosine triphosphate (ATP) synthesis and mitochondrial function related proteins, including ATP5A1, ATP5O, ATP5L, ATP5H, NDUFA, NDUFB, NDUFS, and NDUFV. Serum metabolomic analysis revealed AP upregulated the levels of anti-fatigue amino acids, such as taurine, leucine, arginine, glutamine, lysine, and l-proline. Hepatic proteins express levels, especially tricarboxylic acid (TCA) cycle (CS, SDHB, MDH2, and DLST) and redox-related proteins (SOD1, SOD2, GPX4, and PRDX3), were significantly recovered by AP administration. Spearman correlation analysis uncovered the strong correlation between microbiome, metabolome and proteome, suggesting the anti-fatigue effects of AP is attribute to the energy homeostasis and redox balance through gut-liver axis.
CONCLUSION: AP increased colonic ATP production and improve mitochondrial function by regulating gut microbiota, and further upregulated anti-fatigue amino acid levels in the blood. Based on the gut-liver axis, AP upregulated the hepatic tricarboxylic acid cycle and oxidoreductase-related protein expression, regulating energy homeostasis and redox balance, and ultimately exerting anti-fatigue effects. This study provides insights into the anti-fatigue mechanisms of AP, highlighting its potential as a therapeutic agent.